DTC
CNTB

Deep Track Capital’s Connect Biopharma Holdings CNTB Stock Holding History

Deep Track Capital’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-647,057
Closed -$3.33M – 59
2021
Q4 		$3.33M Buy
+647,057
New +$7.19M 0.24% 52

Other funds holding CNTB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deep Track Capital's CNTB Position: Q1 2022 in Review

Deep Track Capital sold out of Connect Biopharma Holdings (CNTB) in Q1 2022, closing a stake of 647,057 shares — an estimated $3.33M sold.

Deep Track Capital first reported a position in CNTB in Q4 2021 and held it in 1 quarter. The position peaked at $3.33M in Q4 2021. 28 funds tracked by Wall St. Rank hold CNTB as of Q1 2022.

  • Deep Track Capital reported no remaining Connect Biopharma Holdings position as of Q1 2022 after selling out during the quarter.
  • Deep Track Capital sold 647,057 Connect Biopharma Holdings shares in Q1 2022, an estimated $3.33M.
  • Deep Track Capital first reported a position in Connect Biopharma Holdings in Q4 2021 and held it in 1 quarter.
  • Deep Track Capital's Connect Biopharma Holdings position peaked at $3.33M in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2022.

Based on Deep Track Capital's 13F filing for Q1 2022, filed 16 May 2022.